Statins for all by the age of 50 years?

摘要

In The Lancet, the Cholesterol Treatment Trialists' (CTT) Collaborators report a relative risk reduction on statins of about 20% (RR 0-79, 95% CI 0-77-0-81) for major vascular events per 1 mmol/L reduction in LDL cholesterol across different levels of cardiovascular risk. Men and women, old and young, and people with and without cardiovascular disease all benefit. These findings confirm the efficacy of statins for primary prevention, resolving concerns about possible serious adverse effects and potential sources of bias in randomised trials.